New Cambridge-Elan Centre To Focus On Alzheimer's With $10 Million From Elan
This article was originally published in The Pink Sheet Daily
Executive Summary
Ireland's Elan Corp. launches a $10 million center for neuroscience R&D with University of Cambridge academics.
You may also be interested in...
Beyond A-Beta: New Approaches To Alzheimer’s
The Alzheimer’s Association International Conference is under way in Vancouver through July 19, but some of the most anticipated news regarding drug development for the disease is likely to take place later this year. There’s plenty of hope, but not much optimism that pivotal trials for bapneuzumab and solanezumab will succeed. Regardless of the outcome, the results will have an impact on which approaches to Alzheimer’s come next—and how they get funded.
Beyond A-Beta: New Approaches To Alzheimer’s
The track record for anti-amyloid beta Alzheimer’s treatments has been dismal. If upcoming results from pivotal trials for bapineuzumab and solanezumab are disappointing, they won’t scuttle the approach completely, but much more attention would shift toward other targets. We highlight two targets that have gained more attention of late, extracellular tau and ApoE4, and a diverse group of scientists working to move their work forward.
Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up
The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.